DDInter381 DDInter233
Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
Cinacalcet {u} (Compound) resembles {v} (Compound) Propranolol
Propranolol {u} (Compound) resembles {v} (Compound) Levobunolol
Levobunolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Cinacalcet {u} (Compound) resembles {v} (Compound) Duloxetine
Duloxetine {u} (Compound) resembles {v} (Compound) Protriptyline
Protriptyline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Cinacalcet {u} (Compound) resembles {v} (Compound) Naftifine
Naftifine {u} (Compound) resembles {v} (Compound) Toremifene
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Cinacalcet {u} (Compound) resembles {v} (Compound) Duloxetine
Duloxetine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rabeprazole
Rabeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Cinacalcet {u} (Compound) resembles {v} (Compound) Fluoxetine
Fluoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Famotidine
Famotidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Cinacalcet {u} (Compound) resembles {v} (Compound) Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dronabinol
Dronabinol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Cinacalcet {u} (Compound) resembles {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Tolterodine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Cinacalcet {u} (Compound) resembles {v} (Compound) Duloxetine
Duloxetine {u} may lead to a major life threatening interaction when taken with {v} Granisetron
Granisetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Cinacalcet {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Cinacalcet {u} (Compound) resembles {v} (Compound) Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betrixaban
Betrixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Cinacalcet (Compound) resembles Propranolol (Compound) and Propranolol (Compound) resembles Levobunolol (Compound) and Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Cinacalcet (Compound) resembles Duloxetine (Compound) and Duloxetine (Compound) resembles Protriptyline (Compound) and Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Cinacalcet (Compound) resembles Naftifine (Compound) and Naftifine (Compound) resembles Toremifene (Compound) and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Cinacalcet (Compound) resembles Duloxetine (Compound) and Duloxetine may cause a minor interaction that can limit clinical effects when taken with Rabeprazole and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Cinacalcet (Compound) resembles Fluoxetine (Compound) and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Cinacalcet (Compound) resembles Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Cinacalcet (Compound) resembles Dexfenfluramine (Compound) and Dexfenfluramine may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Cinacalcet (Compound) resembles Duloxetine (Compound) and Duloxetine may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Cinacalcet (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Cinacalcet (Compound) resembles Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib